Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice
Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adver...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2025-03-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/97579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388771318956032 |
|---|---|
| author | Minsoo Noh Xiangguo Che Xian Jin Dong-Kyo Lee Hyun-Ju Kim Doo Ri Park Soo Young Lee Hunsang Lee Thomas J Gardella Je-Yong Choi Sihoon Lee |
| author_facet | Minsoo Noh Xiangguo Che Xian Jin Dong-Kyo Lee Hyun-Ju Kim Doo Ri Park Soo Young Lee Hunsang Lee Thomas J Gardella Je-Yong Choi Sihoon Lee |
| author_sort | Minsoo Noh |
| collection | DOAJ |
| description | Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development. |
| format | Article |
| id | doaj-art-0ae91dba372449488adaf05aa06be339 |
| institution | Kabale University |
| issn | 2050-084X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj-art-0ae91dba372449488adaf05aa06be3392025-08-20T03:42:10ZengeLife Sciences Publications LtdeLife2050-084X2025-03-011310.7554/eLife.97579Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female miceMinsoo Noh0https://orcid.org/0000-0002-1239-3783Xiangguo Che1Xian Jin2Dong-Kyo Lee3Hyun-Ju Kim4Doo Ri Park5Soo Young Lee6Hunsang Lee7Thomas J Gardella8Je-Yong Choi9Sihoon Lee10https://orcid.org/0000-0002-9444-5849Department of Internal Medicine and Laboratory of Genomics and Translational Medicine, Gachon University College of Medicine, Incheon, Republic of Korea; Department of Life Sciences, Korea University, Seoul, Republic of KoreaDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of KoreaDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of KoreaDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of KoreaDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of KoreaDepartment of Life Sciences, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, Republic of KoreaDepartment of Life Sciences, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, Republic of KoreaDepartment of Life Sciences, Korea University, Seoul, Republic of KoreaEndocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United StatesDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of KoreaDepartment of Internal Medicine and Laboratory of Genomics and Translational Medicine, Gachon University College of Medicine, Incheon, Republic of KoreaOsteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.https://elifesciences.org/articles/97579parathyroid hormonePTH type-1 receptorbone formationosteoporosis |
| spellingShingle | Minsoo Noh Xiangguo Che Xian Jin Dong-Kyo Lee Hyun-Ju Kim Doo Ri Park Soo Young Lee Hunsang Lee Thomas J Gardella Je-Yong Choi Sihoon Lee Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice eLife parathyroid hormone PTH type-1 receptor bone formation osteoporosis |
| title | Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| title_full | Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| title_fullStr | Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| title_full_unstemmed | Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| title_short | Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| title_sort | dimeric r25cpth 1 34 activates the parathyroid hormone 1 receptor in vitro and stimulates bone formation in osteoporotic female mice |
| topic | parathyroid hormone PTH type-1 receptor bone formation osteoporosis |
| url | https://elifesciences.org/articles/97579 |
| work_keys_str_mv | AT minsoonoh dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT xiangguoche dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT xianjin dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT dongkyolee dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT hyunjukim dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT dooripark dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT sooyounglee dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT hunsanglee dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT thomasjgardella dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT jeyongchoi dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice AT sihoonlee dimericr25cpth134activatestheparathyroidhormone1receptorinvitroandstimulatesboneformationinosteoporoticfemalemice |